All our
news

Discuss, meet & share

Press releases

CE certification for Myrian® 2.14 advanced visualization solution

15 April 2025

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions is fully in line with the Group's strategic roadmap, based on four pillars: innovation, product range extension, geographical expansion and financial control.

See the press release

Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive tomorrow's growth

26 March 2025

Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the certification report was issued on March 26 by the statutory auditors.

See the press release

US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions

20 March 2025

Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted “Breakthrough Device” designation to DUOncoTM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the legal manufacturer.

See the press release

DUOnco Bone : First CE marked  IA algorithm for automatic detection of bone lesions on CT scan

18 March 2025

Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans.

See the press release

CORRECTION - Financial calendar 2025

24 February 2025

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

See the press release

Our
conferences

WebinarsPodcasts

Our
articles

Do you want to receive our news in real time?

Subscribe